What’s in Kazia Therapeutics Limited (KZIA) After Today’s Big Increase?

March 14, 2018 - By Adrian Mccoy

The stock of Kazia Therapeutics Limited (NASDAQ:KZIA) is a huge mover today! The stock increased 4.79% or $0.28 during the last trading session, reaching $6.12. About 116,149 shares traded or 264.07% up from the average. Kazia Therapeutics Limited (NASDAQ:KZIA) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 5 months positive chart setup for the $29.66M company. It was reported on Mar, 14 by Barchart.com. We have $6.43 PT which if reached, will make NASDAQ:KZIA worth $1.48M more.

More notable recent Kazia Therapeutics Limited (NASDAQ:KZIA) news were published by: Marketwatch.com which released: “Kazia Therapeutics Ltd. ADR” on November 24, 2017, also Benzinga.com with their article: “40 Stocks Moving In Friday’s Mid-Day Session” published on February 23, 2018, Marketwatch.com published: “Living Cell Technologies Ltd. ADR” on March 30, 2015. More interesting news about Kazia Therapeutics Limited (NASDAQ:KZIA) were released by: Benzinga.com and their article: “46 Biggest Movers From Yesterday” published on February 26, 2018 as well as Benzinga.com‘s news article titled: “24 Stocks Moving In Friday’s Pre-Market Session” with publication date: February 23, 2018.

Kazia Therapeutics Limited, a biotechnology company, develops anti-cancer drugs. The company has market cap of $29.66 million. It has three technologies, which include phosphoinositide 3-kinase inhibitors, superbenzopyran, and anti-tropomyosin. It currently has negative earnings. The firm is developing GDC-0084, a novel targeted therapy that has completed Phase I clinical trial for the treatment of glioblastoma; Cantrixil, which is in Phase I clinical trials to treat ovarian cancer; and Trilexium, a novel therapy that is in early stage pre-clinical development for the treatment of various cancer types.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: